Literature DB >> 10640522

A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism.

D Cong1, M Doherty, K S Pang.   

Abstract

Processes of intestinal absorption, metabolism, and secretion must be considered simultaneously in viewing oral drug bioavailability. Existing models often fail to predict route-dependent intestinal metabolism, namely, little metabolism occurs after systemic dosing but notable metabolism exists after oral dosing. A physiologically based, Segregated-Flow Model (SFM) was developed to examine the influence of intestinal transport (absorption and exsorption), metabolism, flow, tissue-partitioning characteristics, and elimination in other organs on intestinal clearance, intestinal availability, and systemic bioavailability. For the SFM, blood flow to intestine was effectively segregated for the perfusion of two regions, with 10% reaching an absorptive layer-the enterocytes at the villus tips of the mucosa where metabolic enzymes and the P-glycoprotein reside, and the remaining 90% supplying the rest of the intestine (serosa and submucosa), a nonabsorptive layer. The traditional, physiologically-based model, which regards the intestine as a single, homogeneous compartment with all of the intestinal blood flow perfusing the tissue, was also examined for comparison. The analytical solutions under first order conditions were essentially identical for the SFM and traditional model, differing only in the flow rate to the absorptive/removal region. The presence of other elimination organs did not affect the intestinal clearance and bioavailability estimates, but reduced the percentage of dose metabolized by the intestine. For both models, intestinal availability was inversely related to the intrinsic clearances for intestinal metabolism and exsorption, and was additionally affected by both the rate constant for absorption and that denoting luminal loss when drug was exsorbed. However, the effect of secretion by P-glycoprotein became attenuated with rapid absorption. The difference in flow between models imparted a substantial influence on the intestinal clearance of flow-limited substrates, and the SFM predicted markedly higher extents of intestinal metabolism for oral over i.v. dosing. Thus, the SFM provides a physiological view of the intestine and explains the observation of route-dependent, intestinal metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640522

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

4.  The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.

Authors:  Emile P Chen; Guoying Tai; Harma Ellens
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

5.  Gut instincts: CYP3A4 and intestinal drug metabolism.

Authors:  Kenneth E Thummel
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

Review 6.  Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.

Authors:  K Sandy Pang; Michael Weiss; Panos Macheras
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

Review 7.  Mechanistic approaches to predicting oral drug absorption.

Authors:  Weili Huang; Sau Lawrence Lee; Lawrence X Yu
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

8.  Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.

Authors:  Nicola Melillo; Leon Aarons; Paolo Magni; Adam S Darwich
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-12-14       Impact factor: 2.745

9.  Vitamin D receptor activation induces P-glycoprotein and increases brain efflux of quinidine: an intracerebral microdialysis study in conscious rats.

Authors:  Matthew R Durk; Jianghong Fan; Huadong Sun; Yingbo Yang; Henrianna Pang; K Sandy Pang; Inés A M de Lannoy
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

10.  PKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.

Authors:  Holly P Quach; Qi J Yang; Edwin C Chow; Donald E Mager; Stacie Y Hoi; K Sandy Pang
Journal:  Br J Pharmacol       Date:  2015-05-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.